What information could the main actors of liquid biopsy provide? -a representative case of non-small cell lung cancer (NSCLC)

Aldo Pezzuto, Mariangela Manicone, Maria Chiara Scaini, Alberto Ricci, Salvatore Mariotta, Rita Zamarchi, Elisabetta Rossi

Research output: Contribution to journalArticle

Abstract

In non-small cell lung cancer (NSCLC), there is a consensus regarding the use of liquid biopsy, generally, to detect "druggable" mutations and, in particular, to monitor tyrosine kinase inhibitor (TKI) treatments. However, whether circulating tumor cells (CTCs) are better tools than cell-free DNA (cfDNA), is still a matter of debate, mainly concerning which antigen(s) we should use to investigating simultaneously both epithelial and epithelial-to-mesenchymal transient (EMT) phenotype in the same sample of CTCs. To address this item, we exploited here a single-tube liquid biopsy, to detect both epithelial cell adhesion molecule (EpCAM)-positive CTCs and EpCAM-low/negative CTCs, because down-modulation of EpCAM is considered the first step in EMT. Furthermore, we analyzed the DNA from CTCs of four different phenotypes (ctcDNA), according to their EpCAM expression and cytokeratin pattern, and circulating tumor DNA (ctDNA) by droplet digital PCR (ddPCR), in order to disclose activating and resistance-driving mutations. Liquid biopsy reflected spatial and temporal heterogeneity of the tumor under treatment pressure. We provide the proof-of-concept that the complementary use of ctDNA and ctcDNA represents a reliable, minimally invasive and dynamic tool for a more comprehensive view of tumor evolution.

Original languageEnglish
Pages (from-to)E570-E576
JournalJournal of Thoracic Disease
Volume10
Issue number7
DOIs
Publication statusPublished - Jul 2018

Fingerprint

Circulating Neoplastic Cells
Non-Small Cell Lung Carcinoma
Biopsy
DNA
Neoplasms
Phenotype
Mutation
Keratins
Protein-Tyrosine Kinases
Antigens
Pressure
Polymerase Chain Reaction
Epithelial Cell Adhesion Molecule

Cite this

What information could the main actors of liquid biopsy provide? -a representative case of non-small cell lung cancer (NSCLC). / Pezzuto, Aldo; Manicone, Mariangela; Scaini, Maria Chiara; Ricci, Alberto; Mariotta, Salvatore; Zamarchi, Rita; Rossi, Elisabetta.

In: Journal of Thoracic Disease, Vol. 10, No. 7, 07.2018, p. E570-E576.

Research output: Contribution to journalArticle

Pezzuto, Aldo ; Manicone, Mariangela ; Scaini, Maria Chiara ; Ricci, Alberto ; Mariotta, Salvatore ; Zamarchi, Rita ; Rossi, Elisabetta. / What information could the main actors of liquid biopsy provide? -a representative case of non-small cell lung cancer (NSCLC). In: Journal of Thoracic Disease. 2018 ; Vol. 10, No. 7. pp. E570-E576.
@article{ff0df5313eeb4fb89540dd9d274f57e4,
title = "What information could the main actors of liquid biopsy provide? -a representative case of non-small cell lung cancer (NSCLC)",
abstract = "In non-small cell lung cancer (NSCLC), there is a consensus regarding the use of liquid biopsy, generally, to detect {"}druggable{"} mutations and, in particular, to monitor tyrosine kinase inhibitor (TKI) treatments. However, whether circulating tumor cells (CTCs) are better tools than cell-free DNA (cfDNA), is still a matter of debate, mainly concerning which antigen(s) we should use to investigating simultaneously both epithelial and epithelial-to-mesenchymal transient (EMT) phenotype in the same sample of CTCs. To address this item, we exploited here a single-tube liquid biopsy, to detect both epithelial cell adhesion molecule (EpCAM)-positive CTCs and EpCAM-low/negative CTCs, because down-modulation of EpCAM is considered the first step in EMT. Furthermore, we analyzed the DNA from CTCs of four different phenotypes (ctcDNA), according to their EpCAM expression and cytokeratin pattern, and circulating tumor DNA (ctDNA) by droplet digital PCR (ddPCR), in order to disclose activating and resistance-driving mutations. Liquid biopsy reflected spatial and temporal heterogeneity of the tumor under treatment pressure. We provide the proof-of-concept that the complementary use of ctDNA and ctcDNA represents a reliable, minimally invasive and dynamic tool for a more comprehensive view of tumor evolution.",
author = "Aldo Pezzuto and Mariangela Manicone and Scaini, {Maria Chiara} and Alberto Ricci and Salvatore Mariotta and Rita Zamarchi and Elisabetta Rossi",
year = "2018",
month = "7",
doi = "10.21037/jtd.2018.06.38",
language = "English",
volume = "10",
pages = "E570--E576",
journal = "Journal of Thoracic Disease",
issn = "2072-1439",
publisher = "AME Publishing Company",
number = "7",

}

TY - JOUR

T1 - What information could the main actors of liquid biopsy provide? -a representative case of non-small cell lung cancer (NSCLC)

AU - Pezzuto, Aldo

AU - Manicone, Mariangela

AU - Scaini, Maria Chiara

AU - Ricci, Alberto

AU - Mariotta, Salvatore

AU - Zamarchi, Rita

AU - Rossi, Elisabetta

PY - 2018/7

Y1 - 2018/7

N2 - In non-small cell lung cancer (NSCLC), there is a consensus regarding the use of liquid biopsy, generally, to detect "druggable" mutations and, in particular, to monitor tyrosine kinase inhibitor (TKI) treatments. However, whether circulating tumor cells (CTCs) are better tools than cell-free DNA (cfDNA), is still a matter of debate, mainly concerning which antigen(s) we should use to investigating simultaneously both epithelial and epithelial-to-mesenchymal transient (EMT) phenotype in the same sample of CTCs. To address this item, we exploited here a single-tube liquid biopsy, to detect both epithelial cell adhesion molecule (EpCAM)-positive CTCs and EpCAM-low/negative CTCs, because down-modulation of EpCAM is considered the first step in EMT. Furthermore, we analyzed the DNA from CTCs of four different phenotypes (ctcDNA), according to their EpCAM expression and cytokeratin pattern, and circulating tumor DNA (ctDNA) by droplet digital PCR (ddPCR), in order to disclose activating and resistance-driving mutations. Liquid biopsy reflected spatial and temporal heterogeneity of the tumor under treatment pressure. We provide the proof-of-concept that the complementary use of ctDNA and ctcDNA represents a reliable, minimally invasive and dynamic tool for a more comprehensive view of tumor evolution.

AB - In non-small cell lung cancer (NSCLC), there is a consensus regarding the use of liquid biopsy, generally, to detect "druggable" mutations and, in particular, to monitor tyrosine kinase inhibitor (TKI) treatments. However, whether circulating tumor cells (CTCs) are better tools than cell-free DNA (cfDNA), is still a matter of debate, mainly concerning which antigen(s) we should use to investigating simultaneously both epithelial and epithelial-to-mesenchymal transient (EMT) phenotype in the same sample of CTCs. To address this item, we exploited here a single-tube liquid biopsy, to detect both epithelial cell adhesion molecule (EpCAM)-positive CTCs and EpCAM-low/negative CTCs, because down-modulation of EpCAM is considered the first step in EMT. Furthermore, we analyzed the DNA from CTCs of four different phenotypes (ctcDNA), according to their EpCAM expression and cytokeratin pattern, and circulating tumor DNA (ctDNA) by droplet digital PCR (ddPCR), in order to disclose activating and resistance-driving mutations. Liquid biopsy reflected spatial and temporal heterogeneity of the tumor under treatment pressure. We provide the proof-of-concept that the complementary use of ctDNA and ctcDNA represents a reliable, minimally invasive and dynamic tool for a more comprehensive view of tumor evolution.

U2 - 10.21037/jtd.2018.06.38

DO - 10.21037/jtd.2018.06.38

M3 - Article

C2 - 30174936

VL - 10

SP - E570-E576

JO - Journal of Thoracic Disease

JF - Journal of Thoracic Disease

SN - 2072-1439

IS - 7

ER -